ClinConnect ClinConnect Logo
Search / Trial NCT05312762

To Evaluate the Efficacy and Safety of MaxioCel Versus Aquacel Extra for the Management of Chronic Wounds

Launched by AXIO BIOSOLUTIONS PVT. LTD. · Mar 28, 2022

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is investigating the effectiveness and safety of two different wound dressings, MaxioCel and Aquacel Extra, for treating chronic wounds that ooze, such as diabetic foot ulcers and venous or arterial ulcers. The study will last for 4 weeks, and researchers are looking to see which dressing helps wounds heal better.

To participate, you must be at least 18 years old and have a wound that has not healed for 1 to 24 months, with a size between 1 and 50 square centimeters. Unfortunately, if you have certain health conditions, allergies to the dressings, or are pregnant, you may not be eligible. If you join the study, you'll receive one of the two dressings and will be monitored throughout the trial to see how your wound responds to the treatment. This is a great opportunity for those with chronic wounds to potentially benefit from new treatment options.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male or female 18 years old or above (till 80 years)
  • Patients who are willing to sign the written informed consent
  • Clinically diagnosed with an unhealed or non-healing diabetic foot ulcer / venous ulcer / arterial ulcer / other ulcers / wounds, etc.
  • Wound duration between 1 to 24 months
  • A target wound area between 1 cm2 and 50 cm2
  • Exuding wounds / ulcers
  • Exclusion Criteria:
  • Known allergy/hypersensitivity to the dressing
  • Pregnant women
  • Underlying or diagnosed with serious diseases or deemed unsuitable for this clinical study by the study's clinician
  • Dry wounds
  • Being treated with a high dose of steroids or immunosuppressant therapy or systemic antibiotics
  • Presenting a progressive neoplastic lesion treated with radiotherapy or chemotherapy
  • Patients who had Deep Vein Thrombosis in the previous 3 months
  • Ulcers with clinical signs of infection or erysipelas of the lower limb or biofilm
  • Subjects included in clinical study at present or during the past 30 days
  • Clinical suspicion of osteomyelitis

About Axio Biosolutions Pvt. Ltd.

Axio Biosolutions Pvt. Ltd. is a pioneering biotechnology company dedicated to advancing healthcare solutions through innovative medical technologies. Specializing in the development of advanced wound care products and biosurgical solutions, Axio aims to enhance patient outcomes and streamline clinical practices. With a commitment to rigorous research and development, the company leverages cutting-edge science to create effective, safe, and scalable healthcare products. Their focus on quality and efficacy positions Axio as a trusted partner in the clinical trial landscape, striving to meet the evolving needs of healthcare professionals and patients alike.

Locations

Chennai, Tamil Nadu, India

Chennai, , India

Hyderabad, , India

Vijayawada, , India

Chennai, Tamilnadu, India

Patients applied

0 patients applied

Trial Officials

Shailee Mehta, MSc

Study Chair

Axio Biosolutions Pvt. Ltd.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials